Clinical Trial Update: A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase I/II clinical trial of CR011-vcMMAE in patients with unresectable stage III or stage IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CR011-vcMMAE

Snippet

Sponsor: CuraGen Corporation | Conditions: Unresectable Stage III or Stage IV Melanoma | Phase 1, Phase 2 | Status: COMPLETED